Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Agreement
SIGA Amends International Agreement for Oral TPOXX® Growth
Details : SIGA will lead international promotions for oral TPOXX, an FDA-approved drug for smallpox, while maintaining its contractual relationship with Meridian to ensure continuity for key customers.
Product Name : Tpoxx
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2024
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : SIGA Technologies
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Study Phase : Approved FDF
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...
Product Name : DuoDote
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 14, 2023
Lead Product(s) : Atropine,Pralidoxime Chloride
Therapeutic Area : Pharmacology/Toxicology
Highest Development Status : Approved FDF
Sponsor : ASPR
Deal Size : $9.9 million
Deal Type : Agreement
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : SIGA Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
Details : TPOXX (tecovirimat) receive EMA approval for use in the EU as an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.
Product Name : Tpoxx
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2022
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : SIGA Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Public Health Agency of Canada
Deal Size : $3.4 million
Deal Type : Collaboration
Details : Public Health Agency of Canada has contracted Meridian Medical Technologies for the purchase up to approximately $33 million of oral TPOXX® within five years. TPOXX® is an orally administered antiviral drug for the treatment of human smallpox disease c...
Product Name : Tpoxx
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 13, 2021
Lead Product(s) : Tecovirimat
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Public Health Agency of Canada
Deal Size : $3.4 million
Deal Type : Collaboration